SCHEMBL19709293

SCHEMBL19709293

COc1cc(N2CCNC[C@@H]2C)cc(F)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADAMTS5 Q9UNA0 6/20 0.47
ADAMTS4 O75173 3/20 0.46
HTR2C P28335 7/20 0.44
HTR2A P28223 5/20 0.44
HTR2B P41595 5/20 0.44
ALK Q9UM73 3/20 0.41
MET P08581 1/20 0.41
CHRNB2 P17787 1/20 0.38
CHRNA4 P43681 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
HTR3E A5X5Y0 1/20 0.37
HTR3B O95264 1/20 0.37
HTR3A P46098 1/20 0.37
HTR3D Q70Z44 1/20 0.37
HTR3C Q8WXA8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19709298 0.91 HTR2C (0.46) ADAMTS5HTR2CHTR2AHTR2BCHRNB2
SCHEMBL17884875 0.88 HTR2C (0.44) ADAMTS5HTR2CHTR2AHTR2BSLC6A2
SCHEMBL19709303 0.87 HTR2C (0.45) ADAMTS5ADAMTS4HTR2CHTR2AHTR2B
SCHEMBL19709295 0.87 ADAMTS5 (0.45) ADAMTS5ADAMTS4HTR2CHTR2AHTR2B
SCHEMBL19709537 0.87 ADAMTS5 (0.45) ADAMTS5ADAMTS4HTR2CHTR2AHTR2B
SCHEMBL21461789 0.87 ADAMTS5 (0.45) ADAMTS5ADAMTS4HTR2CHTR2AHTR2B
SCHEMBL19705949 0.86 ADAMTS4 (0.45) ADAMTS5ADAMTS4HTR2CHTR2AHTR2B
SCHEMBL19709302 0.85 HTR2C (0.42) ADAMTS5ADAMTS4HTR2CHTR2AHTR2B
SCHEMBL19709411 0.85 HTR2C (0.46) ADAMTS5ADAMTS4HTR2CHTR2AHTR2B
SCHEMBL19709330 0.82 HTR2C (0.41) ADAMTS5HTR2CHTR2AHTR2BALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3468955-B1 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS GALAPAGOS NV (BE) 2021-01-06 EP disclosed
US-10829478-B2 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis GALAPAGOS NV (BE) 2020-11-10 US disclosed
US-10829478-B2 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis GALAPAGOS NV (BE) 2020-11-10 US disclosed
US-20190315719-A1 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS GALAPAGOS NV (BE) 2019-10-17 US disclosed
US-20190315719-A1 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS GALAPAGOS NV (BE) 2019-10-17 US disclosed
WO-2017211666-A1 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS GALAPAGOS NV (BE) 2017-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190315719-A1 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS ADAMTS5, ADAMTS4, ADAMTS1 ADAMTS5 1/4885ADAMTS4 2/4885HTR2C 980/4885
US-10829478-B2 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis ADAMTS5, ADAMTS4, ADAMTS1 ADAMTS5 1/4885ADAMTS4 2/4885HTR2C 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.